The EGFR-specific tyrosine kinase inhibitor (TKI) erlotinib has been explored as an antitumor agent in HNSCC [27] and shows a selective efficacy in HNSCC patients [28,29]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.